Ceftriaxone Market, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Ceftriaxone Market size was valued at USD 2,010.32 Million in 2023, expanding at a CAGR of 3.29% from 2024 to 2032.

Ceftriaxone is a broad-spectrum cephalosporin antibiotic utilized for treating various bacterial infections. It functions by inhibiting the synthesis of bacterial cell walls, effectively killing or stunting the growth of susceptible bacteria. This antibiotic is commonly advised for conditions such as meningitis, pneumonia, and infections of the skin, urinary tract, and abdomen. Ceftriaxone can be administered intravenously or intramuscularly, ensuring a rapid absorption and effectiveness. Its long half-life allows for once-daily dosing in many instances, making it a convenient option for both hospital and outpatient settings. Ceftriaxone is recognized for its efficacy against diverse range of pathogens, establishing it as a cornerstone of an empirical antibiotic therapy. As a cephalosporin beta-lactam antibiotic, it targets bacterial infections caused by typically susceptible gram-positive organisms. In vitro studies have demonstrated that ceftriaxone is effective against gram-positive, gram-negative, and anaerobic bacteria. Its bactericidal action is attributed to its inhibition of cell wall synthesis, which occurs through binding to penicillin-binding proteins (PBPs).

Ceftriaxone Market- Market Dynamics

Increasing awareness among the public, and the rising geriatric population that is more susceptible to bacterial diseases to propel market demand

Ceftriaxone is administered via intravenous or intramuscular injection. When taken orally, its bioavailability is less than 1%. It is primarily used to treat urinary tract infections, intra-abdominal infections, endocarditis, acute bacterial otitis media, meningitis, and pneumonia. Additionally, ceftriaxone serves as the first-line treatment for neurosyphilis in patients who are allergic to penicillin. The injection is also given prior to certain surgeries to prevent post-operative infections. Common side effects of ceftriaxone include pain, hardness, tenderness, pale skin, diarrhea, weakness, and shortness of breath during exercise. However, it is important to note that ceftriaxone is ineffective against viral infections such as colds and the flu. The medication is available only with a doctor's prescription. The global ceftriaxone market is expected to grow in the near future due to the increasing incidence of urinary tract infections (UTIs), heightened awareness among the public, and the rising geriatric population that is more susceptible to bacterial diseases. The prevalence of major chronic diseases worldwide is anticipated to rise significantly in the coming years. The demand for ceftriaxone injections is being driven by the growing occurrence of UTIs, acute bacterial otitis media, intra-abdominal infections, and other bacterial conditions. UTIs, often caused by bacteria entering the bladder, are particularly common among women, with more than half likely to experience at least one UTI in their lifetime. These infections can be painful and pose serious health risks. The increasing use of ceftriaxone for treating UTIs is projected to contribute to the expansion of the ceftriaxone market. According to the National Center for Biotechnology Information, approximately 80% of children are expected to experience at least one episode of otitis media during their lifetime, with 80% to 90% likely to have otitis media with effusion before reaching school age. Moreover, the rising geriatric population, particularly in developed countries, is likely to increase the demand for ceftriaxone injections, as bacterial infections are more prevalent among individuals over the age of 65.

Ceftriaxone Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.29% over the forecast period (2024-2032)

Based on Indication segmentation, pneumonia was predicted to show maximum market share in the year 2023

Based on Distribution Channel segmentation, hospital pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Ceftriaxone Market- Segmentation Analysis:

The Global Ceftriaxone Market is segmented on the basis of Indication, Distribution Channel, and Region.

The market is divided into seven categories based on Indication: Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia and Others. In the ceftriaxone market, pneumonia is the leading indication, driven by the rising prevalence of both community-acquired and hospital-acquired pneumonia, particularly among vulnerable groups such as the elderly and immunocompromised patients. Ceftriaxone's broad-spectrum efficacy against a wide range of pathogens positions it as a first-line treatment, frequently administered in hospital settings for its effectiveness in managing severe cases. While other indications, such as urinary tract infections and meningitis, are also notable, the high incidence of pneumonia and the urgent need for effective treatment solidify its status as the primary indication for ceftriaxone.

The market is divided into three categories based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. In the distribution channel segment, hospital pharmacies are the dominant in the ceftriaxone market. This predominance is primarily due to drug's primary use in inpatient settings for treating serious infections that necessitate immediate medical attention. Hospital pharmacies are essential for ensuring timely access to ceftriaxone for patients requiring critical care. Although retail and online pharmacies are significant for outpatient management, the urgent demand for ceftriaxone in hospital environments drives the majority of its sales through hospital pharmacies, highlighting the critical nature of the infections it addresses.

Ceftriaxone Market- Geographical Insights

This market covers North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. Participating nations within these regions create sub-segments within the market. In 2023, North America held the largest share of the ceftriaxone market, positioning itself as a highly lucrative region for growth during the forecast period. This dominance can be attributed to the rising incidence of bacterial infections. Furthermore, the region benefits from a high adoption rate of technologically advanced products, significant healthcare expenditure, early access to innovative technologies, and favorable funding from governments and charitable organizations for healthcare research. These factors are expected to drive the expansion of the ceftriaxone market in the coming years. The U.S. emerged as the leader within North America, largely due to the presence of key industry players.

Ceftriaxone Market- Competitive Landscape:

Companies in the ceftriaxone market implement a variety of strategies to remain competitive and foster growth. Ongoing research and development efforts are dedicated to improving formulations, such as creating extended-release versions or combination therapies aimed at resistant strains. Strategic alliances with healthcare providers and institutions facilitate clinical trials and broaden the drug's application in various medical environments. Marketing initiatives emphasize the drug's efficacy, safety profile, and versatility in treating common infections, targeting both prescribers and hospitals. Furthermore, companies often participate in educational campaigns to raise awareness about the appropriate use of antibiotics, promoting ceftriaxone as a first-line treatment while addressing concerns regarding antibiotic resistance.

Recent Developments:

In September 2021, the Government of India implemented an anti-dumping duty on ceftriaxone raw materials imported from China to safeguard domestic manufacturers from low-cost imports.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CEFTRIAXONE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Hikma Pharmaceuticals plc
Qilu Pharmaceutical Co. Ltd.
Novartis AG
Baxter International, Inc.
Aurobindo Pharma
ACS DOBFAR S.P.A.
Orchid Pharma
Nectar Lifesciences Ltd.
Lupin Pharmaceuticals
Others

GLOBAL CEFTRIAXONE MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Urinary Tract Infections
Intra-abdominal Infections
Endocarditis
Acute Bacterial Otitis Media
Meningitis
Pneumonia
Others

GLOBAL CEFTRIAXONE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

GLOBAL CEFTRIAXONE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4060

1. Ceftriaxone Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Ceftriaxone Market Snippet by Indication
- 2.1.2. Ceftriaxone Market Snippet by Distribution Channel
- 2.1.3. Ceftriaxone Market Snippet by Country
- 2.1.4. Ceftriaxone Market Snippet by Region
2.2. Competitive Insights

3. Ceftriaxone Key Market Trends

3.1. Ceftriaxone Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Ceftriaxone Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Ceftriaxone Market Opportunities
3.4. Ceftriaxone Market Future Trends

4. Ceftriaxone Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Ceftriaxone Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Ceftriaxone Market Landscape

6.1. Ceftriaxone Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Ceftriaxone Market - By Indication

7.1. Overview
- 7.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
- 7.1.2. Urinary Tract Infections
- 7.1.3. Intra-abdominal Infections
- 7.1.4. Endocarditis
- 7.1.5. Acute Bacterial Otitis Media
- 7.1.6. Meningitis
- 7.1.7. Pneumonia
- 7.1.8. Others

8. Ceftriaxone Market - By Distribution Channel

8.1. Overview
- 8.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 8.1.2. Hospital Pharmacies
- 8.1.3. Retail Pharmacies
- 8.1.4. Online Pharmacies

9. Ceftriaxone Market- By Geography

9.1. Introduction
- 9.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
9.2. North America
- 9.2.1. Overview
- 9.2.2. Ceftriaxone Key Manufacturers in North America
- 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.2.4. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.6. U.S.
  - 9.2.6.1. Overview
  - 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.6.3. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.2.6.4. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.2.7. Canada
  - 9.2.7.1. Overview
  - 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.2.7.3. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.2.7.4. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.3. Europe
- 9.3.1. Overview
- 9.3.2. Ceftriaxone Key Manufacturers in Europe
- 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.3.4. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.6. Germany
  - 9.3.6.1. Overview
  - 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.6.3. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.6.4. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.7. Italy
  - 9.3.7.1. Overview
  - 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.7.3. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.7.4. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.8. United Kingdom
  - 9.3.8.1. Overview
  - 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.8.3. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.8.4. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.9. France
  - 9.3.9.1. Overview
  - 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.9.3. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.10. Russia
  - 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.10.2. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.10.3. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.11. Netherlands
  - 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.11.2. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.11.3. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.12. Sweden
  - 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.12.2. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.12.3. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.13. Poland
  - 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.13.2. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.13.3. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.3.14. Rest of Europe
  - 9.3.14.1. Overview
  - 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.3.14.3. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.3.14.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
- 9.4.1. Overview
- 9.4.2. Ceftriaxone Key Manufacturers in Asia Pacific
- 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.4.4. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.6. India
  - 9.4.6.1. Overview
  - 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.6.3. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.6.4. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.7. China
  - 9.4.7.1. Overview
  - 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.7.3. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.8. Japan
  - 9.4.8.1. Overview
  - 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.8.3. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.8.4. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.9. South Korea
  - 9.4.9.1. Overview
  - 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.9.3. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.10. Australia
  - 9.4.10.1. Overview
  - 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.10.3. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.10.4. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.11. Thailand
  - 9.4.11.1. Overview
  - 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.11.3. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.12. Indonesia
  - 9.4.12.1. Overview
  - 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.12.3. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.13. Philippines
  - 9.4.13.1. Overview
  - 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.13.3. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.4.14. Rest of APAC
  - 9.4.14.1. Overview
  - 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.4.14.3. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.5. Latin America
- 9.5.1. Overview
- 9.5.2. Ceftriaxone Key Manufacturers in Latin America
- 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.5.4. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.6. Brazil
  - 9.5.6.1. Overview
  - 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.6.3. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.5.6.4. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.7. Mexico
  - 9.5.7.1. Overview
  - 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.7.3. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.5.7.4. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.8. Argentina
  - 9.5.8.1. Overview
  - 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.8.3. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.5.8.4. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.9. Colombia
  - 9.5.9.1. Overview
  - 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.9.3. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.5.9.4. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.5.10. Rest of LATAM
  - 9.5.10.1. Overview
  - 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.5.10.3. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa
- 9.6.1. Overview
- 9.6.2. Ceftriaxone Key Manufacturers in Middle East and Africa
- 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 9.6.4. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.6. Saudi Arabia
  - 9.6.6.1. Overview
  - 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.6.3. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.7. United Arab Emirates
  - 9.6.7.1. Overview
  - 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.7.3. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.6.7.4. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.8. Israel
  - 9.6.8.1. Overview
  - 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.8.3. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.6.8.4. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.9. Turkey
  - 9.6.9.1. Overview
  - 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.9.3. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.6.9.4. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.10. Algeria
  - 9.6.10.1. Overview
  - 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.10.3. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.6.10.4. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.11. Egypt
  - 9.6.11.1. Overview
  - 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.11.3. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.6.11.4. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 9.6.12. Rest of MEA
  - 9.6.12.1. Overview
  - 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 9.6.12.3. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Ceftriaxone Industry

10.1. Competitive Dashboard
10.2. Company Profiles
- 10.2.1. Hikma Pharmaceuticals plc
- 10.2.2. Qilu Pharmaceutical Co. Ltd.
- 10.2.3. Novartis AG
- 10.2.4. Baxter International, Inc.
- 10.2.5. Aurobindo Pharma
- 10.2.6. ACS DOBFAR S.P.A.
- 10.2.7. Orchid Pharma
- 10.2.8. Nectar Lifesciences Ltd.
- 10.2.9. Lupin Pharmaceuticals
- 10.2.10. Others

11. 360 Degree Analyst View

12. Appendix

12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us